Du är här

2015-10-13

Orion Oyj: Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015

ORION CORPORATION STOCK EXCHANGE RELEASE 13 OCTOBER 2015 at 2:30 P.M.
EEST

Publishing of Orion Corporation's Interim Report for January-September 2015 on
27 October 2015

Orion will publish its Interim Report for January-September 2015 on Tuesday,
27 October 2015 approximately at 12:00 noon Finnish time (EET). The release
and related presentation material in Finnish and in English will be available
on the Group's homepage atwww.orion.fi/en/investorspromptly after the
publishing.

News conference for analysts and mediaA news conference for analysts and media will be held on Tuesday 27 October
2015 at 13:30 EET at Hotel Kämp,
address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will
give a brief presentation in English on the financial review. Questions can
be asked after the result presentation.

Participants should be prepared to present a photo ID on request.

Live webcast and conference callA link to the live webcast will be available at Orion's
websitewww.orion.fi/en/investors.

The conference call ID is 955325 and the phone numbers to participate the
conference are:

Finland: +358 (0)9 2313 9202
Sweden: +46 (0)8 5052 0114
UK: +44 (0)207 1620 177
USA: +1 334 323 6203

News conference recordingsA recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent periodThe silent period preceding the publication is ongoing and continues until the
disclosure.

Orion Corporation

----------------------------------
| Timo Lappalainen Jari Karlson |
|President and CEO |
| CFO |
----------------------------------
Contact person:

Tuukka Hirvonen, Communications Manager, IR&Financial Communications
tel. +358 10 426 2721

Publisher:

Orion Corporation

www.orion.fi/en
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

HUG#1958499

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.